MRNA Vaccine Plus Keytruda Delays Skin Cancer Return
17th April 2023
An experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin cancer by 44% compared with Merck’s immunotherapy Keytruda alone, U.S. researchers reported at a medical meeting on Sunday.
The findings suggest that adding a personalized cancer vaccine based on mRNA technology to Keytruda, which revs up the immune response, could prolong the time patients have without recurrence or death, said Dr. Jeffrey Weber of the NYU Langone Perlmutter Cancer Center, who presented the findings.
Good news.
April 17th, 2023 at 14:44
Trying experimental mRNA shots on people with deadly skin cancer sounds reasonable, mandating them on healthy individuals to perhaps avoid a nasty cold is not.
April 17th, 2023 at 19:44
The difficulty is to get the agents of the Deep State to appreciate the difference.